Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abbreviated-course rituximab for refractory autoimmune disorders
ACTRN12606000495527Phase 2Not yet recruiting
- Sponsor
- Melbourne Health
- Start
- Jan 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in autoimmune disease, sponsored by Melbourne Health. Primary endpoints: Response rate and Durability of response. Planned start Jan 2007; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on ACTRN12606000495527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000495527.